BeiGene Newsroom

BeiGene's Strong Financial and Clinical Prospects Solidify Buy Rating

TipRanksAug 9 12:27 ET

BeiGene Analyst Ratings

BenzingaAug 8 15:14 ET

BeiGene's Brukinsa Drives Strong Growth and Justifies Buy Rating

TipRanksAug 8 07:28 ET

Buy Rating for BeiGene Backed by Brukinsa's Market Growth and Strong Financial Outlook

TipRanksAug 7 15:22 ET

Nomura Adjusts BeiGene's Price Target to HK$158.37 From HK$150, Keeps at Buy

MT NewswiresJul 16 03:26 ET

B of A Securities Maintains Neutral on BeiGene, Lowers Price Target to $152.5

BenzingaJul 9 13:22 ET

BeiGene Analyst Ratings

BenzingaJul 9 13:21 ET

BeiGene Analysis: Hold Rating Amidst Mixed Drug Sales Performance and Market Competition

TipRanksJul 9 06:37 ET

BeiGene Performance Analysis: A Hold Rating With Cautious Optimism Amidst Competitive Pressures

TipRanksMay 15 05:52 ET

BeiGene's Soaring Sales and Path to Profitability Reinforce Buy Rating

TipRanksMay 10 02:16 ET

Buy Rating Affirmed for BeiGene on Strong Q4 Performance and Promising Brukinsa Sales

TipRanksMay 10 01:30 ET

BeiGene Analyst Ratings

BenzingaMay 9 12:17 ET

BeiGene (BGNE) Receives a Hold From Bernstein

TipRanksApr 25 03:55 ET

BeiGene Analyst Ratings

BenzingaApr 24 13:27 ET

BeiGene Analyst Ratings

BenzingaApr 8 12:37 ET

Bernstein Adjusts BeiGene's Price Target to $161 From $196, Maintains Market Perform Rating

MT NewswiresMar 27 06:27 ET

BeiGene Analyst Ratings

BenzingaMar 27 04:50 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE) and BeiGene (BGNE)

TipRanksMar 26 19:55 ET

BeiGene: Hold Recommendation Amidst Mixed Financial Indicators and Robust Drug Pipeline Growth

TipRanksMar 15 08:32 ET

UBS Cuts BeiGene Stock Target to $285.70, Maintains Buy Rating

InvestingFeb 29 10:32 ET